SCHEMBL3058741

SCHEMBL3058741

Cc1cnccc1C(=O)N(Cc1cccc(Cl)c1)c1cccc(C)c1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 2/20 0.48
NOS1 P29475 2/20 0.48
NOS2 P35228 2/20 0.48
ALDH1A1 P00352 3/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
LMNA P02545 1/20 0.45
PDK1 Q15118 4/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PDK2 Q15119 1/20 0.43
PDK3 Q15120 1/20 0.43
PDK4 Q16654 1/20 0.43
GPBAR1 Q8TDU6 2/20 0.43
NR3C1 P04150 1/20 0.41
TRPM8 Q7Z2W7 1/20 0.40
GLA P06280 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
GRM5 P41594 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3050510 0.89 ALDH1A1 (0.46) NOS3NOS1NOS2ALDH1A1MEN1
SCHEMBL3043499 0.89 NOS3 (0.49) NOS3NOS1NOS2MEN1KMT2A
SCHEMBL3057326 0.89 TRPM8 (0.51) ALDH1A1MEN1KMT2ALMNAPDK1
SCHEMBL3050032 0.86 NOS3 (0.55) NOS3NOS1NOS2PDK1TSHR
SCHEMBL3058307 0.83 NOS3 (0.53) NOS3NOS1NOS2PDK1PDK2
SCHEMBL3052473 0.82 NOS3 (0.61) NOS3NOS1NOS2ALDH1A1PDK1
SCHEMBL3064987 0.81 KDM4C (0.45) NOS3NOS1NOS2ALDH1A1MEN1
SCHEMBL3050876 0.81 PDK1 (0.46) NOS3NOS1NOS2MEN1KMT2A
SCHEMBL3048580 0.80 RAB9A (0.44) NOS3NOS1NOS2ALDH1A1LMNA
SCHEMBL3177779 0.80 TRPM8 (0.62) ALDH1A1MEN1KMT2ALMNAPDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100261758-A1 HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS NOVARTIS AG (CH) 2010-10-14 US disclosed
CN-101405268-A Amide derivatives and their use for the treatment of protein-related diseases NOVARTIS AG (CH) 2009-04-08 CN disclosed
EP-2001851-A2 AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREAMENT OF G PROTEIN RELATED DISEASES Novartis AG (CH) 2008-12-17 EP disclosed
WO-2007110237-A2 AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREATMENT OF G PROTEIN RELATED DISEASES NOVARTIS AG (CH) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261758-A1 HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS HRH4, CNR1, CNR2 NOS3 3019/4885NOS1 3682/4885NOS2 3548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.